Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5 Lymphoid 3 Myeloid 2 Plasma cell 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 871 Bortezomib 457 Lenalidomide 456 Cyclophosphamide 365 Melphalan 272 Calcium Dobesilate 263 daratumumab 234 pomalidomide 208 carfilzomib 182 fludarabine phosphate 140 fludarabine 136 Thalidomide 125 Peripheral Blood Stem Cell Transplantation 119 Filgrastim 114 ixazomib 93 Mycophenolic Acid 90 Granulocyte Colony-Stimulating Factor 89 Whole-Body Irradiation 87 Busulfan 87 dexamethasone acetate 86 Tacrolimus 78 dexamethasone 21-phosphate 74 isatuximab 69 Cyclosporine 68 auricularum 67 Prednisone 65 elotuzumab 58 belantamab mafodotin 57 Antilymphocyte Serum 56 Etoposide 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × letermovir × Plasma cell × Clear all

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡